Lung Cancer—Non-Small Cell Metastatic

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.

 CTI: NCT03215706

 

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Joseph Vallejo, Pallavi Shruti Mishra-Kalyani, et al.

 

 
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, et al.
 
 Clinical trial information: NCT02367781; NCT02657434; NCT02366143
 
 
 
 
 
 
 
 Clinical trial information: NCT03260491
 
 
 Clinical trial information: NCT03974022